KEYTRUDA Market Drug Insight
The report "KEYTRUDA Market Size, Forecast, and Drug Insights – 2032" offers an in-depth analysis of both market and emerging insights regarding KEYTRUDA for the treatment of Pancreatic Cancer, Cholangiocarcinoma (CCA), Malignant Pleural Mesothelioma (MPM), Diffuse Large B-cell Lymphoma (DLBCL), Ovarian Cancer, and Urothelial Carcinoma (UCC) in the seven major markets. A detailed picture of KEYTRUDA in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of KEYTRUDA. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the KEYTRUDA market forecast analysis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Pancreatic Cancer, Cholangiocarcinoma (CCA), malignant pleural mesothelioma (MPM), Diffuse Large B-cell lymphoma (DLBCL), ovarian cancer, and Urothelial Carcinoma (UCC).
Drug Summary
KEYTRUDA (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) therapy that works upon increasing the ability of the body’s immune system to help detect and fight tumor cells. It is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1, and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
It is used to treat adult pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
Dosage and Administration
For adults, the recommended dosage is 200 mg every 3 weeks or 400 mg every 6 weeks; for pediatrics 2 mg/kg (up to 200 mg) every 3 weeks.
Mechanism of Action
Binding the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells inhibits T cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibiting active T-cell immune surveillance of tumors. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the antitumor immune response. The tumor growth decreased in syngeneic mouse tumor models, by blocking PD-1 activity.
Recent Developments
- In January 2025, Merck is working to diversify its pipeline ahead of the anticipated loss of patent protection for Keytruda, its top-selling PD-1 inhibitor. With more than 40 approved indications, Keytruda generated over $21.6 billion in the first nine months of 2024. However, with biosimilars expected to enter the market starting in 2028, Merck is focusing on strengthening its pipeline to mitigate the anticipated sales decline.
Scope of the Report
The report provides insights into:
- A comprehensive product overview including the KEYTRUDA description, mechanism of action, dosage and administration, research and development activities in Pancreatic Cancer, Cholangiocarcinoma (CCA), malignant pleural mesothelioma (MPM), Diffuse Large B-cell lymphoma (DLBCL), ovarian cancer, and Urothelial Carcinoma (UCC).
- Elaborated details on KEYTRUDA regulatory milestones and other development activities have been provided in this report.
- The report also highlights the KEYTRUDA research and development activities in Pancreatic Cancer, Cholangiocarcinoma (CCA), malignant pleural mesothelioma (MPM), Diffuse Large B-cell lymphoma (DLBCL), ovarian cancer, and Urothelial Carcinoma (UCC) across the United States, Europe, and Japan.
- The report also covers the patents information with expiry timeline around KEYTRUDA.
- The report contains forecasted sales of for Pancreatic Cancer, Cholangiocarcinoma (CCA), malignant pleural mesothelioma (MPM), Diffuse Large B-cell lymphoma (DLBCL), ovarian cancer, and Urothelial Carcinoma (UCC) till 2032.
- Comprehensive coverage of the late-stage emerging therapies for Pancreatic Cancer, Cholangiocarcinoma (CCA), malignant pleural mesothelioma (MPM), Diffuse Large B-cell lymphoma (DLBCL), ovarian cancer, and Urothelial Carcinoma (UCC).
- The report also features the SWOT analysis with analyst views for KEYTRUDA in Pancreatic Cancer, Cholangiocarcinoma (CCA), malignant pleural mesothelioma (MPM), Diffuse Large B-cell lymphoma (DLBCL), ovarian cancer, and Urothelial Carcinoma (UCC).
Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
KEYTRUDA Analytical Perspective by DelveInsight
In-depth KEYTRUDA Market Assessment
This report provides a detailed market and emerging assessment of KEYTRUDA for Pancreatic Cancer, Cholangiocarcinoma (CCA), malignant pleural mesothelioma (MPM), Diffuse Large B-cell lymphoma (DLBCL), ovarian cancer, and Urothelial Carcinoma (UCC) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
KEYTRUDA Clinical Assessment
The report provides the clinical trials information of KEYTRUDA covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
- In the coming years, the market scenario for Pancreatic Cancer, Cholangiocarcinoma (CCA), malignant pleural mesothelioma (MPM), Diffuse Large B-cell lymphoma (DLBCL), ovarian cancer, and Urothelial Carcinoma (UCC). is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence KEYTRUDA dominance.
- Other emerging products for Pancreatic Cancer, Cholangiocarcinoma (CCA), malignant pleural mesothelioma (MPM), Diffuse Large B-cell lymphoma (DLBCL), ovarian cancer, and Urothelial Carcinoma (UCC). are expected to give tough market competition to KEYTRUDA and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of KEYTRUDA in Pancreatic Cancer, Cholangiocarcinoma (CCA), malignant pleural mesothelioma (MPM), Diffuse Large B-cell lymphoma (DLBCL), ovarian cancer, and Urothelial Carcinoma (UCC)..
- Our in-depth analysis of the forecasted sales data of KEYTRUDA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the KEYTRUDA in Pancreatic Cancer, Cholangiocarcinoma (CCA), malignant pleural mesothelioma (MPM), Diffuse Large B-cell lymphoma (DLBCL), ovarian cancer, and Urothelial Carcinoma (UCC)..
Key Questions
- What is the product type, route of administration and mechanism of action of KEYTRUDA?
- What is the clinical trial status of the study related to KEYTRUDA in Pancreatic Cancer, Cholangiocarcinoma (CCA), malignant pleural mesothelioma (MPM), Diffuse Large B-cell lymphoma (DLBCL), ovarian cancer, and Urothelial Carcinoma (UCC) and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the KEYTRUDA development?
- What are the key designations that have been granted to KEYTRUDA for Pancreatic Cancer, Cholangiocarcinoma (CCA), malignant pleural mesothelioma (MPM), Diffuse Large B-cell lymphoma (DLBCL), ovarian cancer, and Urothelial Carcinoma (UCC)?
- What is the forecasted market scenario of KEYTRUDA for Pancreatic Cancer, Cholangiocarcinoma (CCA), malignant pleural mesothelioma (MPM), Diffuse Large B-cell lymphoma (DLBCL), ovarian cancer, and Urothelial Carcinoma (UCC)?
- What are the forecasted sales of KEYTRUDA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
- What are the other emerging products available and how are these giving competition to KEYTRUDA for Pancreatic Cancer, Cholangiocarcinoma (CCA), malignant pleural mesothelioma (MPM), Diffuse Large B-cell lymphoma (DLBCL), ovarian cancer, and Urothelial Carcinoma (UCC)?
- Which are the late-stage emerging therapies under development for the treatment of Pancreatic Cancer, Cholangiocarcinoma (CCA), malignant pleural mesothelioma (MPM), Diffuse Large B-cell lymphoma (DLBCL), ovarian cancer, and Urothelial Carcinoma (UCC)?
